ID   CHK1_HUMAN              Reviewed;         476 AA.
AC   O14757; A8K934; B4DDD0; B4DSK3; B5BTY6; F5H7S4; H2BI51;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=Serine/threonine-protein kinase Chk1;
DE            EC=2.7.11.1;
DE   AltName: Full=CHK1 checkpoint homolog;
DE   AltName: Full=Cell cycle checkpoint kinase;
DE   AltName: Full=Checkpoint kinase-1;
GN   Name=CHEK1; Synonyms=CHK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF
RP   CDC25A; CDC25B AND CDC25C, INTERACTION WITH CDC25A; CDC25B AND CDC25C,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MUTAGENESIS OF ASP-130, AND
RP   VARIANT VAL-471.
RX   PubMed=9278511; DOI=10.1126/science.277.5331.1497;
RA   Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H.,
RA   Elledge S.J.;
RT   "Conservation of the Chk1 checkpoint pathway in mammals: linkage of
RT   DNA damage to Cdk regulation through Cdc25.";
RL   Science 277:1497-1501(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND VARIANT VAL-471.
RX   PubMed=9382850; DOI=10.1016/S0960-9822(06)00417-9;
RA   Flaggs G., Plug A.W., Dunks K.M., Mundt K.E., Ford J.C.,
RA   Quiggle M.R.E., Taylor E.M., Westphal C.H., Ashley T., Hoekstra M.F.,
RA   Carr A.M.;
RT   "Atm-dependent interactions of a mammalian chk1 homolog with meiotic
RT   chromosomes.";
RL   Curr. Biol. 7:977-986(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-471.
RX   PubMed=10717241;
RA   Semba S., Ouyang H., Han S.-Y., Kato Y., Horii A.;
RT   "Analysis of the candidate target genes for mutation in microsatellite
RT   instability-positive cancers of the colorectum, stomach, and
RT   endometrium.";
RL   Int. J. Oncol. 16:731-737(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Fetal thymus;
RX   PubMed=22184239; DOI=10.1073/pnas.1104767109;
RA   Pabla N., Bhatt K., Dong Z.;
RT   "Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous
RT   inhibitor of Chk1 that regulates cell cycle and DNA damage
RT   checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:197-202(2012).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT VAL-471.
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-156 AND VAL-471.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-471.
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-471.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-471.
RC   TISSUE=Bone marrow, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-130.
RX   PubMed=10673501;
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RT   "The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2)
RT   phosphorylate p53 at multiple DNA damage-inducible sites.";
RL   Genes Dev. 14:289-300(2000).
RN   [12]
RP   ERRATUM.
RA   Shieh S.-Y., Ahn J., Tamai K., Taya Y., Prives C.;
RL   Genes Dev. 14:750-750(2000).
RN   [13]
RP   PHOSPHORYLATION AT SER-345 BY ATR.
RX   PubMed=10859164;
RA   Liu Q., Guntuku S., Cui X.-S., Matsuoka S., Cortez D., Tamai K.,
RA   Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A.,
RA   Elledge S.J.;
RT   "Chk1 is an essential kinase that is regulated by Atr and required for
RT   the G(2)/M DNA damage checkpoint.";
RL   Genes Dev. 14:1448-1459(2000).
RN   [14]
RP   FUNCTION IN DNA REPLICATION, PHOSPHORYLATION BY ATR, AND MUTAGENESIS
RP   OF ASP-130.
RX   PubMed=11535615; DOI=10.1083/jcb.200104099;
RA   Feijoo C., Hall-Jackson C., Wu R., Jenkins D., Leitch J.,
RA   Gilbert D.M., Smythe C.;
RT   "Activation of mammalian Chk1 during DNA replication arrest: a role
RT   for Chk1 in the intra-S phase checkpoint monitoring replication origin
RT   firing.";
RL   J. Cell Biol. 154:913-923(2001).
RN   [15]
RP   PHOSPHORYLATION AT SER-317 AND SER-345, AND MUTAGENESIS OF ASP-130;
RP   SER-317; SER-345; SER-357; SER-366 AND SER-468.
RX   PubMed=11390642; DOI=10.1128/MCB.21.13.4129-4139.2001;
RA   Zhao H., Piwnica-Worms H.;
RT   "ATR-mediated checkpoint pathways regulate phosphorylation and
RT   activation of human Chk1.";
RL   Mol. Cell. Biol. 21:4129-4139(2001).
RN   [16]
RP   SUBSTRATE SPECIFICITY, AND MUTAGENESIS OF ASP-130.
RX   PubMed=11821419; DOI=10.1074/jbc.M111705200;
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RT   "Determination of substrate motifs for human Chk1 and hCds1/Chk2 by
RT   the oriented peptide library approach.";
RL   J. Biol. Chem. 277:16102-16115(2002).
RN   [17]
RP   ERRATUM.
RA   O'Neill T., Giarratani L., Chen P., Iyer L., Lee C.-H., Bobiak M.,
RA   Kanai F., Zhou B.-B., Chung J.H., Rathbun G.A.;
RL   J. Biol. Chem. 277:35776-35777(2002).
RN   [18]
RP   FUNCTION IN DNA DAMAGE RESPONSE, PHOSPHORYLATION AT SER-317 AND
RP   SER-345, AND MUTAGENESIS OF LYS-38.
RX   PubMed=12446774; DOI=10.1128/MCB.22.24.8552-8561.2002;
RA   Heffernan T.P., Simpson D.A., Frank A.R., Heinloth A.N., Paules R.S.,
RA   Cordeiro-Stone M., Kaufmann W.K.;
RT   "An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation
RT   following UVC-induced DNA damage.";
RL   Mol. Cell. Biol. 22:8552-8561(2002).
RN   [19]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH BRCA1.
RX   PubMed=11836499; DOI=10.1038/ng837;
RA   Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., Brody L.C.;
RT   "BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon
RT   DNA damage.";
RL   Nat. Genet. 30:285-289(2002).
RN   [20]
RP   FUNCTION IN DNA DAMAGE RESPONSE.
RX   PubMed=12399544; DOI=10.1073/pnas.182557299;
RA   Zhao H., Watkins J.L., Piwnica-Worms H.;
RT   "Disruption of the checkpoint kinase 1/cell division cycle 25A pathway
RT   abrogates ionizing radiation-induced S and G2 checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14795-14800(2002).
RN   [21]
RP   FUNCTION IN CDC25A TURNOVER, PHOSPHORYLATION AT SER-317 AND SER-345,
RP   AND MUTAGENESIS OF SER-317 AND SER-345.
RX   PubMed=12676583; DOI=10.1016/S1535-6108(03)00048-5;
RA   Soerensen C.S., Syljuaesen R.G., Falck J., Schroeder T.,
RA   Roennstrand L., Khanna K.K., Zhou B.-B., Bartek J., Lukas J.;
RT   "Chk1 regulates the S phase checkpoint by coupling the physiological
RT   turnover and ionizing radiation-induced accelerated proteolysis of
RT   Cdc25A.";
RL   Cancer Cell 3:247-258(2003).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF TLK1, AND PHOSPHORYLATION AT SER-317.
RX   PubMed=12660173; DOI=10.1093/emboj/cdg151;
RA   Groth A., Lukas J., Nigg E.A., Sillje H.H.W., Wernstedt C., Bartek J.,
RA   Hansen K.;
RT   "Human tousled like kinases are targeted by an ATM- and Chk1-dependent
RT   DNA damage checkpoint.";
RL   EMBO J. 22:1676-1687(2003).
RN   [23]
RP   FUNCTION IN CDC25A TURNOVER, AND MUTAGENESIS OF ASP-130.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J.,
RA   Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A
RT   protein phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [24]
RP   PHOSPHORYLATION AT SER-317, AND MUTAGENESIS OF ASP-130; SER-317 AND
RP   SER-345.
RX   PubMed=12588868; DOI=10.1074/jbc.M210862200;
RA   Gatei M., Sloper K., Soerensen C., Syljuaesen R., Falck J., Hobson K.,
RA   Savage K., Lukas J., Zhou B.-B., Bartek J., Khanna K.K.;
RT   "Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent
RT   phosphorylation of Chk1 on ser-317 in response to ionizing
RT   radiation.";
RL   J. Biol. Chem. 278:14806-14811(2003).
RN   [25]
RP   FUNCTION IN CDC25A TURNOVER, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=12676925; DOI=10.1074/jbc.M300229200;
RA   Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H.,
RA   Fesik S., Zhang H.;
RT   "Chk1 mediates S and G2 arrests through Cdc25A degradation in response
RT   to DNA-damaging agents.";
RL   J. Biol. Chem. 278:21767-21773(2003).
RN   [26]
RP   INTERACTION WITH YWHAZ AND XPO1, SUBCELLULAR LOCATION, ASSOCIATION
RP   WITH CHROMATIN, PHOSPHORYLATION AT SER-317 AND SER-345, AND
RP   MUTAGENESIS OF SER-317; PHE-344; SER-345 AND MET-353.
RX   PubMed=12676962; DOI=10.1074/jbc.M300070200;
RA   Jiang K., Pereira E., Maxfield M., Russell B., Goudelock D.M.,
RA   Sanchez Y.;
RT   "Regulation of Chk1 includes chromatin association and 14-3-3 binding
RT   following phosphorylation on ser-345.";
RL   J. Biol. Chem. 278:25207-25217(2003).
RN   [27]
RP   FUNCTION IN CDC25A TURNOVER.
RX   PubMed=12759351; DOI=10.1074/jbc.M302704200;
RA   Hassepass I., Voit R., Hoffmann I.;
RT   "Phosphorylation at serine 75 is required for UV-mediated degradation
RT   of human Cdc25A phosphatase at the S-phase checkpoint.";
RL   J. Biol. Chem. 278:29824-29829(2003).
RN   [28]
RP   INTERACTION WITH CLSPN.
RX   PubMed=12766152; DOI=10.1074/jbc.M301136200;
RA   Chini C.C.S., Chen J.;
RT   "Human claspin is required for replication checkpoint control.";
RL   J. Biol. Chem. 278:30057-30062(2003).
RN   [29]
RP   FUNCTION IN MITOSIS, AND FUNCTION IN PHOSPHORYLATION OF CDC25A.
RX   PubMed=14559997; DOI=10.1128/MCB.23.21.7488-7497.2003;
RA   Chen M.-S., Ryan C.E., Piwnica-Worms H.;
RT   "Chk1 kinase negatively regulates mitotic function of Cdc25A
RT   phosphatase through 14-3-3 binding.";
RL   Mol. Cell. Biol. 23:7488-7497(2003).
RN   [30]
RP   REGULATION OF TLK1.
RX   PubMed=12955071; DOI=10.1038/sj.onc.1206691;
RA   Krause D.R., Jonnalagadda J.C., Gatei M.H., Sillje H.H.W., Zhou B.-B.,
RA   Nigg E.A., Khanna K.;
RT   "Suppression of tousled-like kinase activity after DNA damage or
RT   replication block requires ATM, NBS1 and Chk1.";
RL   Oncogene 22:5927-5937(2003).
RN   [31]
RP   PHOSPHORYLATION AT SER-317.
RX   PubMed=14657349; DOI=10.1073/pnas.2536810100;
RA   Wang Y., Qin J.;
RT   "MSH2 and ATR form a signaling module and regulate two branches of the
RT   damage response to DNA methylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003).
RN   [32]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=14988723; DOI=10.1038/sj.emboj.7600113;
RA   Pichierri P., Rosselli F.;
RT   "The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and
RT   ATR-NBS1-FANCD2 pathways.";
RL   EMBO J. 23:1178-1187(2004).
RN   [33]
RP   DOMAIN, MITOTIC PHOSPHORYLATION, PHOSPHORYLATION AT SER-345, AND
RP   MUTAGENESIS OF LYS-38.
RX   PubMed=14681223; DOI=10.1074/jbc.M312215200;
RA   Ng C.-P., Lee H.C., Ho C.W., Arooz T., Siu W.Y., Lau A., Poon R.Y.C.;
RT   "Differential mode of regulation of the checkpoint kinases CHK1 and
RT   CHK2 by their regulatory domains.";
RL   J. Biol. Chem. 279:8808-8819(2004).
RN   [34]
RP   FUNCTION IN MITOSIS, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-130.
RX   PubMed=15311285; DOI=10.1038/ncb1165;
RA   Kraemer A., Mailand N., Lukas C., Syljuaesen R.G., Wilkinson C.J.,
RA   Nigg E.A., Bartek J., Lukas J.;
RT   "Centrosome-associated Chk1 prevents premature activation of cyclin-B-
RT   Cdk1 kinase.";
RL   Nat. Cell Biol. 6:884-891(2004).
RN   [35]
RP   INTERACTION WITH CLSPN, AND PHOSPHORYLATION AT SER-296; SER-317 AND
RP   SER-345.
RX   PubMed=15707391; DOI=10.1042/BJ20041966;
RA   Clarke C.A.L., Clarke P.R.;
RT   "DNA-dependent phosphorylation of Chk1 and claspin in a human cell-
RT   free system.";
RL   Biochem. J. 388:705-712(2005).
RN   [36]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15710331; DOI=10.1016/j.ccr.2005.01.009;
RA   Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L.,
RA   Mansukhani M., Murty V.V.V.S., Gaciong Z., Meek S.E.M.,
RA   Piwnica-Worms H., Hibshoosh H., Parsons R.;
RT   "Lack of PTEN sequesters CHK1 and initiates genetic instability.";
RL   Cancer Cell 7:193-204(2005).
RN   [37]
RP   INTERACTION WITH PPM1D, PHOSPHORYLATION AT SER-317 AND SER-345, AND
RP   DEPHOSPHORYLATION BY PPM1D.
RX   PubMed=15870257; DOI=10.1101/gad.1291305;
RA   Lu X., Nannenga B., Donehower L.A.;
RT   "PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle
RT   checkpoints.";
RL   Genes Dev. 19:1162-1174(2005).
RN   [38]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, AND FUNCTION IN TP53-DEPENDENT
RP   TRANSCRIPTION.
RX   PubMed=15659650; DOI=10.1091/mbc.E04-08-0689;
RA   Ou Y.-H., Chung P.-H., Sun T.-P., Shieh S.-Y.;
RT   "p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the
RT   regulation of DNA-damage-induced C-terminal acetylation.";
RL   Mol. Biol. Cell 16:1684-1695(2005).
RN   [39]
RP   INTERACTION WITH TIMELESS.
RX   PubMed=15798197; DOI=10.1128/MCB.25.8.3109-3116.2005;
RA   Uensal-Kacmaz K., Mullen T.E., Kaufmann W.K., Sancar A.;
RT   "Coupling of human circadian and cell cycles by the timeless
RT   protein.";
RL   Mol. Cell. Biol. 25:3109-3116(2005).
RN   [40]
RP   FUNCTION IN HOMOLOGOUS RECOMBINATION REPAIR, FUNCTION IN
RP   PHOSPHORYLATION OF RAD51, INTERACTION WITH RAD51, AND MUTAGENESIS OF
RP   SER-317 AND SER-345.
RX   PubMed=15665856; DOI=10.1038/ncb1212;
RA   Soerensen C.S., Hansen L.T., Dziegielewski J., Syljuaesen R.G.,
RA   Lundin C., Bartek J., Helleday T.;
RT   "The cell-cycle checkpoint kinase Chk1 is required for mammalian
RT   homologous recombination repair.";
RL   Nat. Cell Biol. 7:195-201(2005).
RN   [41]
RP   FUNCTION IN MITOTIC EXIT, AND PHOSPHORYLATION AT SER-345.
RX   PubMed=15650047; DOI=10.1073/pnas.0409130102;
RA   Huang X., Tran T., Zhang L., Hatcher R., Zhang P.;
RT   "DNA damage-induced mitotic catastrophe is mediated by the Chk1-
RT   dependent mitotic exit DNA damage checkpoint.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1065-1070(2005).
RN   [42]
RP   FUNCTION IN TP53 ACTIVATION, AND FUNCTION IN PHOSPHORYLATION OF MDM4.
RX   PubMed=16511572; DOI=10.1038/sj.emboj.7601010;
RA   Jin Y., Dai M.S., Lu S.Z., Xu Y., Luo Z., Zhao Y., Lu H.;
RT   "14-3-3gamma binds to MDMX that is phosphorylated by UV-activated
RT   Chk1, resulting in p53 activation.";
RL   EMBO J. 25:1207-1218(2006).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF CLSPN, AND INTERACTION WITH CLSPN.
RX   PubMed=16963448; DOI=10.1074/jbc.M604373200;
RA   Chini C.C., Chen J.;
RT   "Repeated phosphopeptide motifs in human Claspin are phosphorylated by
RT   Chk1 and mediate Claspin function.";
RL   J. Biol. Chem. 281:33276-33282(2006).
RN   [44]
RP   FUNCTION IN PHOSPHORYLATION OF RB1.
RX   PubMed=17380128; DOI=10.1038/sj.emboj.7601652;
RA   Inoue Y., Kitagawa M., Taya Y.;
RT   "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between
RT   pRB and E2F-1 after DNA damage.";
RL   EMBO J. 26:2083-2093(2007).
RN   [45]
RP   FUNCTION IN DNA CROSS-LINKS REPAIR, AND FUNCTION IN PHOSPHORYLATION OF
RP   FANCE.
RX   PubMed=17296736; DOI=10.1128/MCB.02357-06;
RA   Wang X., Kennedy R.D., Ray K., Stuckert P., Ellenberger T.,
RA   D'Andrea A.D.;
RT   "Chk1-mediated phosphorylation of FANCE is required for the Fanconi
RT   anemia/BRCA pathway.";
RL   Mol. Cell. Biol. 27:3098-3108(2007).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [47]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=18510930; DOI=10.1016/j.cell.2008.03.037;
RA   Sidi S., Sanda T., Kennedy R.D., Hagen A.T., Jette C.A., Hoffmans R.,
RA   Pascual J., Imamura S., Kishi S., Amatruda J.F., Kanki J.P.,
RA   Green D.R., D'Andrea A.A., Look A.T.;
RT   "Chk1 suppresses a caspase-2 apoptotic response to DNA damage that
RT   bypasses p53, Bcl-2, and caspase-3.";
RL   Cell 133:864-877(2008).
RN   [48]
RP   FUNCTION IN PHOSPHORYLATION OF NEK6.
RX   PubMed=18728393; DOI=10.4161/cc.7.17.6551;
RA   Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I.,
RA   Chung J.H., Yun J.;
RT   "Nek6 is involved in G2/M phase cell cycle arrest through DNA damage-
RT   induced phosphorylation.";
RL   Cell Cycle 7:2705-2709(2008).
RN   [49]
RP   FUNCTION IN REPLICATION FORK MAINTENANCE, AND FUNCTION IN PCNA
RP   UBIQUITINATION.
RX   PubMed=18451105; DOI=10.1101/gad.1632808;
RA   Yang X.H., Shiotani B., Classon M., Zou L.;
RT   "Chk1 and Claspin potentiate PCNA ubiquitination.";
RL   Genes Dev. 22:1147-1152(2008).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [51]
RP   FUNCTION IN RAD51-MEDIATED DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION
RP   OF BRCA2 AND RAD51.
RX   PubMed=18317453; DOI=10.1038/onc.2008.17;
RA   Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z.,
RA   Hasty P.E., Stambrook P.J.;
RT   "The checkpoint kinases Chk1 and Chk2 regulate the functional
RT   associations between hBRCA2 and Rad51 in response to DNA damage.";
RL   Oncogene 27:3977-3985(2008).
RN   [52]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-296 AND
RP   SER-301, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [53]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [54]
RP   INTERACTION WITH CDK5RAP3.
RX   PubMed=19223857; DOI=10.1038/cr.2009.14;
RA   Jiang H., Wu J., He C., Yang W., Li H.;
RT   "Tumor suppressor protein C53 antagonizes checkpoint kinases to
RT   promote cyclin-dependent kinase 1 activation.";
RL   Cell Res. 19:458-468(2009).
RN   [55]
RP   PHOSPHORYLATION AT SER-345, UBIQUITINATION AT LYS-436, INTERACTION
RP   WITH FBXO6, AND MUTAGENESIS OF SER-345; ARG-372; ARG-376; ARG-379 AND
RP   LYS-436.
RX   PubMed=19716789; DOI=10.1016/j.molcel.2009.06.030;
RA   Zhang Y.-W., Brognard J., Coughlin C., You Z., Dolled-Filhart M.,
RA   Aslanian A., Manning G., Abraham R.T., Hunter T.;
RT   "The F box protein Fbx6 regulates Chk1 stability and cellular
RT   sensitivity to replication stress.";
RL   Mol. Cell 35:442-453(2009).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [57]
RP   FUNCTION IN NEK11 PHOSPHORYLATION.
RX   PubMed=19734889; DOI=10.1038/ncb1969;
RA   Melixetian M., Klein D.K., Soerensen C.S., Helin K.;
RT   "NEK11 regulates CDC25A degradation and the IR-induced G2/M
RT   checkpoint.";
RL   Nat. Cell Biol. 11:1247-1253(2009).
RN   [58]
RP   INTERACTION WITH FEM1B.
RX   PubMed=19330022; DOI=10.1038/onc.2009.58;
RA   Sun T.P., Shieh S.Y.;
RT   "Human FEM1B is required for Rad9 recruitment and CHK1 activation in
RT   response to replication stress.";
RL   Oncogene 28:1971-1981(2009).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-301, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [60]
RP   FUNCTION IN CDC25A DEGRADATION.
RX   PubMed=20090422; DOI=10.4161/cc.9.3.10513;
RA   Soerensen C.S., Melixetian M., Klein D.K., Helin K.;
RT   "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling.";
RL   Cell Cycle 9:450-455(2010).
RN   [61]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-286; SER-296 AND
RP   SER-301, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [62]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [63]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [64]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280; SER-296; SER-301;
RP   SER-331; SER-467 AND SER-468, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-289.
RX   PubMed=10761933; DOI=10.1016/S0092-8674(00)80704-7;
RA   Chen P., Luo C., Deng Y., Ryan K., Register J., Margosiak S.,
RA   Tempczyk-Russell A., Nguyen B., Myers P., Lundgren K., Kan C.-C.,
RA   O'Connor P.M.;
RT   "The 1.7 A crystal structure of human cell cycle checkpoint kinase
RT   Chk1: implications for Chk1 regulation.";
RL   Cell 100:681-692(2000).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-289.
RX   PubMed=12244092; DOI=10.1074/jbc.M201233200;
RA   Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T.,
RA   Johanson K.O., Green S.M., Concha N.O., Zhou B.-B.S.;
RT   "Structural basis for Chk1 inhibition by UCN-01.";
RL   J. Biol. Chem. 277:46609-46615(2002).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-289.
RX   PubMed=15974586; DOI=10.1021/jm049022c;
RA   Foloppe N., Fisher L.M., Howes R., Kierstan P., Potter A.,
RA   Robertson A.G.S., Surgenor A.E.;
RT   "Structure-based design of novel Chk1 inhibitors: insights into
RT   hydrogen bonding and protein-ligand affinity.";
RL   J. Med. Chem. 48:4332-4345(2005).
RN   [68]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-223 AND MET-312.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is required for
CC       checkpoint-mediated cell cycle arrest and activation of DNA repair
CC       in response to the presence of DNA damage or unreplicated DNA. May
CC       also negatively regulate cell cycle progression during unperturbed
CC       cell cycles. This regulation is achieved by a number of mechanisms
CC       that together help to preserve the integrity of the genome.
CC       Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to
CC       and phosphorylates CDC25A, CDC25B and CDC25C. Phosphorylation of
CC       CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at
CC       'Ser-216' creates binding sites for 14-3-3 proteins which inhibit
CC       CDC25A and CDC25C. Phosphorylation of CDC25A at 'Ser-76', 'Ser-
CC       124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of
CC       CDC25A. Phosphorylation of CDC25A at 'Ser-76' primes the protein
CC       for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88'
CC       by NEK11, which is required for polyubiquitination and degradation
CC       of CDCD25A. Inhibition of CDC25 leads to increased inhibitory
CC       tyrosine phosphorylation of CDK-cyclin complexes and blocks cell
CC       cycle progression. Also phosphorylates NEK6. Binds to and
CC       phosphorylates RAD51 at 'Thr-309', which promotes the release of
CC       RAD51 from BRCA2 and enhances the association of RAD51 with
CC       chromatin, thereby promoting DNA repair by homologous
CC       recombination. Phosphorylates multiple sites within the C-terminus
CC       of TP53, which promotes activation of TP53 by acetylation and
CC       promotes cell cycle arrest and suppression of cellular
CC       proliferation. Also promotes repair of DNA cross-links through
CC       phosphorylation of FANCE. Binds to and phosphorylates TLK1 at
CC       'Ser-743', which prevents the TLK1-dependent phosphorylation of
CC       the chromatin assembly factor ASF1A. This may enhance chromatin
CC       assembly both in the presence or absence of DNA damage. May also
CC       play a role in replication fork maintenance through regulation of
CC       PCNA. May regulate the transcription of genes that regulate cell-
CC       cycle progression through the phosphorylation of histones.
CC       Phosphorylates histone H3.1 (to form H3T11ph), which leads to
CC       epigenetic inhibition of a subset of genes. May also phosphorylate
CC       RB1 to promote its interaction with the E2F family of
CC       transcription factors and subsequent cell cycle arrest.
CC   -!- FUNCTION: Isoform 2: Endogenous repressor of isoform 1, interacts
CC       with, and antagonizes CHK1 to promote the S to G2/M phase
CC       transition.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated through phosphorylation predominantly
CC       by ATR but also by ATM in response to DNA damage or inhibition of
CC       DNA replication. Activation is modulated by several mediators
CC       including CLSPN, BRCA1 and FEM1B.
CC   -!- SUBUNIT: Interacts (phosphorylated by ATR) with RAD51. Interacts
CC       with and phosphorylates CLSPN, an adapter protein that regulates
CC       the ATR-dependent phosphorylation of CHEK1. Interacts with BRCA1.
CC       Interacts with and phosphorylates CDC25A, CDC25B and CDC25C.
CC       Interacts with FBXO6, which regulates CHEK1. Interacts with PPM1D,
CC       which regulates CHEK1 through dephosphorylation. Interacts with
CC       TIMELESS; DNA damage-dependent. Interacts with FEM1B; activates
CC       CHEK1 in response to stress. Interacts with TLK1. Interacts with
CC       XPO1 and YWHAZ. Isoform 1 associates with isoform 2, the
CC       interaction is disrupted upon phosphorylation by ATR. Interacts
CC       with CDK5RAP3; antagonizes CHEK1 (PubMed:19223857).
CC       {ECO:0000269|PubMed:11836499, ECO:0000269|PubMed:12676962,
CC       ECO:0000269|PubMed:12766152, ECO:0000269|PubMed:15665856,
CC       ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15798197,
CC       ECO:0000269|PubMed:15870257, ECO:0000269|PubMed:16963448,
CC       ECO:0000269|PubMed:19223857, ECO:0000269|PubMed:19330022,
CC       ECO:0000269|PubMed:19716789, ECO:0000269|PubMed:9278511}.
CC   -!- INTERACTION:
CC       P38398:BRCA1; NbExp=3; IntAct=EBI-974488, EBI-349905;
CC       P30307:CDC25C; NbExp=2; IntAct=EBI-974488, EBI-974439;
CC       Q95KV1:CHUK (xeno); NbExp=3; IntAct=EBI-974488, EBI-7669068;
CC       Q9HAW4:CLSPN; NbExp=5; IntAct=EBI-974488, EBI-1369377;
CC       Q9UJM3:ERRFI1; NbExp=2; IntAct=EBI-974488, EBI-2941912;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-974488, EBI-352572;
CC       O00255:MEN1; NbExp=2; IntAct=EBI-974488, EBI-592789;
CC       Q06609:RAD51; NbExp=3; IntAct=EBI-974488, EBI-297202;
CC       P06400:RB1; NbExp=3; IntAct=EBI-974488, EBI-491274;
CC       Q9HCE7-2:SMURF1; NbExp=4; IntAct=EBI-974488, EBI-9845742;
CC       Q9UNS1:TIMELESS; NbExp=2; IntAct=EBI-974488, EBI-2212315;
CC       P61981:YWHAG; NbExp=7; IntAct=EBI-974488, EBI-359832;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Note=Nuclear export is
CC       mediated at least in part by XPO1/CRM1. Also localizes to the
CC       centrosome specifically during interphase, where it may protect
CC       centrosomal CDC2 kinase from inappropriate activation by
CC       cytoplasmic CDC25B.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O14757-1; Sequence=Displayed;
CC       Name=2; Synonyms=Chk1-short, Chk1-S;
CC         IsoId=O14757-2; Sequence=VSP_044008, VSP_044009;
CC       Name=3;
CC         IsoId=O14757-3; Sequence=VSP_045075;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously with the most abundant
CC       expression in thymus, testis, small intestine and colon.
CC       {ECO:0000269|PubMed:9278511, ECO:0000269|PubMed:9382850}.
CC   -!- DOMAIN: The autoinhibitory region (AIR) inhibits the activity of
CC       the kinase domain. {ECO:0000269|PubMed:14681223}.
CC   -!- PTM: Phosphorylated by ATR in a RAD17-dependent manner in response
CC       to ultraviolet irradiation and inhibition of DNA replication.
CC       Phosphorylated by ATM in response to ionizing irradiation. ATM and
CC       ATR can both phosphorylate Ser-317 and Ser-345 and this results in
CC       enhanced kinase activity. Phosphorylation at Ser-345 induces a
CC       change in the conformation of the protein, activates the kinase
CC       activity and is a prerequisite for interaction with FBXO6 and
CC       subsequent ubiquitination at Lys-436. Phosphorylation at Ser-345
CC       also increases binding to 14-3-3 proteins and promotes nuclear
CC       retention. Conversely, dephosphorylation at Ser-345 by PPM1D may
CC       contribute to exit from checkpoint mediated cell cycle arrest.
CC       Phosphorylation at Ser-280 by AKT1/PKB, may promote mono and/or
CC       diubiquitination. Also phosphorylated at undefined residues during
CC       mitotic arrest, resulting in decreased activity.
CC       {ECO:0000269|PubMed:10859164, ECO:0000269|PubMed:11390642,
CC       ECO:0000269|PubMed:12446774, ECO:0000269|PubMed:12588868,
CC       ECO:0000269|PubMed:12660173, ECO:0000269|PubMed:12676583,
CC       ECO:0000269|PubMed:12676925, ECO:0000269|PubMed:12676962,
CC       ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14681223,
CC       ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15650047,
CC       ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257,
CC       ECO:0000269|PubMed:19716789}.
CC   -!- PTM: Ubiquitinated. Mono or diubiquitination promotes nuclear
CC       exclusion (By similarity). The activated form (phosphorylated on
CC       Ser-345) is polyubiquitinated at Lys-436 by some SCF-type E3
CC       ubiquitin ligase complex containing FBXO6 promoting its
CC       degradation. Ubiquitination and degradation are required to
CC       terminate the checkpoint and ensure that activated CHEK1 does not
CC       accumulate as cells progress through S phase, when replication
CC       forks encounter transient impediments during normal DNA
CC       replication. {ECO:0000250, ECO:0000269|PubMed:10859164,
CC       ECO:0000269|PubMed:11390642, ECO:0000269|PubMed:12446774,
CC       ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925,
CC       ECO:0000269|PubMed:12676962, ECO:0000269|PubMed:14681223,
CC       ECO:0000269|PubMed:14988723, ECO:0000269|PubMed:15650047,
CC       ECO:0000269|PubMed:15707391, ECO:0000269|PubMed:15870257,
CC       ECO:0000269|PubMed:19716789}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. NIM1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/chek1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF016582; AAC51736.1; -; mRNA.
DR   EMBL; AF032874; AAB88852.1; -; mRNA.
DR   EMBL; AB032387; BAA84577.1; -; Genomic_DNA.
DR   EMBL; JF289264; AEB71796.1; -; mRNA.
DR   EMBL; AK292549; BAF85238.1; -; mRNA.
DR   EMBL; AK293143; BAG56691.1; -; mRNA.
DR   EMBL; AK299783; BAG61665.1; -; mRNA.
DR   EMBL; AF527555; AAM78553.1; -; Genomic_DNA.
DR   EMBL; AB451222; BAG70036.1; -; mRNA.
DR   EMBL; AB451345; BAG70159.1; -; mRNA.
DR   EMBL; AP001132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67644.1; -; Genomic_DNA.
DR   EMBL; BC004202; AAH04202.1; -; mRNA.
DR   EMBL; BC017575; AAH17575.1; -; mRNA.
DR   CCDS; CCDS58191.1; -. [O14757-3]
DR   CCDS; CCDS81645.1; -. [O14757-2]
DR   CCDS; CCDS8459.1; -. [O14757-1]
DR   RefSeq; NP_001107593.1; NM_001114121.2. [O14757-1]
DR   RefSeq; NP_001107594.1; NM_001114122.2. [O14757-1]
DR   RefSeq; NP_001231775.1; NM_001244846.1. [O14757-3]
DR   RefSeq; NP_001265.2; NM_001274.5. [O14757-1]
DR   RefSeq; NP_001317357.1; NM_001330428.1. [O14757-2]
DR   RefSeq; XP_016872635.1; XM_017017146.1. [O14757-1]
DR   UniGene; Hs.24529; -.
DR   UniGene; Hs.595920; -.
DR   PDB; 1IA8; X-ray; 1.70 A; A=1-289.
DR   PDB; 1NVQ; X-ray; 2.00 A; A=1-289.
DR   PDB; 1NVR; X-ray; 1.80 A; A=1-289.
DR   PDB; 1NVS; X-ray; 1.80 A; A=1-289.
DR   PDB; 1ZLT; X-ray; 1.74 A; A=1-289.
DR   PDB; 1ZYS; X-ray; 1.70 A; A=1-273.
DR   PDB; 2AYP; X-ray; 2.90 A; A=1-269.
DR   PDB; 2BR1; X-ray; 2.00 A; A=1-289.
DR   PDB; 2BRB; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRG; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRH; X-ray; 2.10 A; A=1-289.
DR   PDB; 2BRM; X-ray; 2.20 A; A=1-289.
DR   PDB; 2BRN; X-ray; 2.80 A; A=1-289.
DR   PDB; 2BRO; X-ray; 2.20 A; A=1-289.
DR   PDB; 2C3J; X-ray; 2.10 A; A=1-289.
DR   PDB; 2C3K; X-ray; 2.60 A; A=1-289.
DR   PDB; 2C3L; X-ray; 2.35 A; A=1-289.
DR   PDB; 2CGU; X-ray; 2.50 A; A=1-289.
DR   PDB; 2CGV; X-ray; 2.60 A; A=1-289.
DR   PDB; 2CGW; X-ray; 2.20 A; A=1-289.
DR   PDB; 2CGX; X-ray; 2.20 A; A=1-289.
DR   PDB; 2E9N; X-ray; 2.50 A; A=2-270.
DR   PDB; 2E9O; X-ray; 2.10 A; A=2-270.
DR   PDB; 2E9P; X-ray; 2.60 A; A=2-270.
DR   PDB; 2E9U; X-ray; 2.00 A; A=2-270.
DR   PDB; 2E9V; X-ray; 2.00 A; A/B=2-269.
DR   PDB; 2GDO; X-ray; 3.00 A; A=1-289.
DR   PDB; 2GHG; X-ray; 3.50 A; A=2-270.
DR   PDB; 2HOG; X-ray; 1.90 A; A=2-307.
DR   PDB; 2HXL; X-ray; 1.80 A; A=2-307.
DR   PDB; 2HXQ; X-ray; 2.00 A; A=2-307.
DR   PDB; 2HY0; X-ray; 1.70 A; A=2-307.
DR   PDB; 2QHM; X-ray; 2.00 A; A=1-307.
DR   PDB; 2QHN; X-ray; 1.70 A; A=1-307.
DR   PDB; 2R0U; X-ray; 1.90 A; A=1-307.
DR   PDB; 2WMQ; X-ray; 2.48 A; A=1-289.
DR   PDB; 2WMR; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMS; X-ray; 2.70 A; A=1-289.
DR   PDB; 2WMT; X-ray; 2.55 A; A=1-289.
DR   PDB; 2WMU; X-ray; 2.60 A; A=1-289.
DR   PDB; 2WMV; X-ray; 2.01 A; A=1-289.
DR   PDB; 2WMW; X-ray; 2.43 A; A=1-289.
DR   PDB; 2WMX; X-ray; 2.45 A; A=1-289.
DR   PDB; 2X8D; X-ray; 1.90 A; A=1-289.
DR   PDB; 2X8E; X-ray; 2.50 A; A=1-276.
DR   PDB; 2X8I; X-ray; 1.92 A; A=1-289.
DR   PDB; 2XEY; X-ray; 2.70 A; A=1-289.
DR   PDB; 2XEZ; X-ray; 2.25 A; A=1-289.
DR   PDB; 2XF0; X-ray; 2.40 A; A=1-289.
DR   PDB; 2YDI; X-ray; 1.60 A; A=1-289.
DR   PDB; 2YDJ; X-ray; 1.85 A; A/B=1-276.
DR   PDB; 2YDK; X-ray; 1.90 A; A=1-276.
DR   PDB; 2YER; X-ray; 1.83 A; A=1-276.
DR   PDB; 2YEX; X-ray; 1.30 A; A=1-276.
DR   PDB; 2YM3; X-ray; 2.01 A; A=1-289.
DR   PDB; 2YM4; X-ray; 2.35 A; A=1-289.
DR   PDB; 2YM5; X-ray; 2.03 A; A=1-289.
DR   PDB; 2YM6; X-ray; 2.01 A; A=1-289.
DR   PDB; 2YM7; X-ray; 1.81 A; A=1-289.
DR   PDB; 2YM8; X-ray; 2.07 A; A=1-289.
DR   PDB; 2YWP; X-ray; 2.90 A; A=2-270.
DR   PDB; 3F9N; X-ray; 1.90 A; A=2-307.
DR   PDB; 3JVR; X-ray; 1.76 A; A=2-272.
DR   PDB; 3JVS; X-ray; 1.90 A; A=2-272.
DR   PDB; 3NLB; X-ray; 1.90 A; A=1-289.
DR   PDB; 3OT3; X-ray; 1.44 A; A=2-274.
DR   PDB; 3OT8; X-ray; 1.65 A; A=2-274.
DR   PDB; 3PA3; X-ray; 1.40 A; A=2-274.
DR   PDB; 3PA4; X-ray; 1.59 A; A=2-274.
DR   PDB; 3PA5; X-ray; 1.70 A; A=2-274.
DR   PDB; 3TKH; X-ray; 1.79 A; A=1-307.
DR   PDB; 3TKI; X-ray; 1.60 A; A=1-307.
DR   PDB; 3U9N; X-ray; 1.85 A; A=2-274.
DR   PDB; 4FSM; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSN; X-ray; 2.10 A; A=4-280.
DR   PDB; 4FSQ; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FSR; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FST; X-ray; 1.90 A; A=2-270.
DR   PDB; 4FSU; X-ray; 2.10 A; A=2-280.
DR   PDB; 4FSW; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSY; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FSZ; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FT0; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FT3; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FT5; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FT7; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FT9; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTA; X-ray; 2.40 A; A=2-280.
DR   PDB; 4FTC; X-ray; 2.00 A; A=2-280.
DR   PDB; 4FTI; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTJ; X-ray; 2.20 A; A=2-280.
DR   PDB; 4FTK; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FTL; X-ray; 2.50 A; A=2-280.
DR   PDB; 4FTM; X-ray; 1.90 A; A=2-280.
DR   PDB; 4FTN; X-ray; 2.02 A; A=2-280.
DR   PDB; 4FTO; X-ray; 2.10 A; A=2-280.
DR   PDB; 4FTQ; X-ray; 2.00 A; A=2-280.
DR   PDB; 4FTR; X-ray; 2.25 A; A=2-280.
DR   PDB; 4FTT; X-ray; 2.30 A; A=2-280.
DR   PDB; 4FTU; X-ray; 2.10 A; A=2-280.
DR   PDB; 4GH2; X-ray; 2.03 A; A=2-280.
DR   PDB; 4HYH; X-ray; 1.70 A; A=1-289.
DR   PDB; 4HYI; X-ray; 1.40 A; A=1-289.
DR   PDB; 4JIK; X-ray; 1.90 A; A=2-274.
DR   PDB; 4QYE; X-ray; 2.05 A; A=1-289.
DR   PDB; 4QYF; X-ray; 2.15 A; A=1-289.
DR   PDB; 4QYG; X-ray; 1.75 A; A/B=1-289.
DR   PDB; 4QYH; X-ray; 1.90 A; A/B=1-289.
DR   PDB; 4RVK; X-ray; 1.85 A; A=1-289.
DR   PDB; 4RVL; X-ray; 1.85 A; A=1-289.
DR   PDB; 4RVM; X-ray; 1.86 A; A=1-289.
DR   PDB; 5DLS; X-ray; 2.15 A; A=1-289.
DR   PDB; 5F4N; X-ray; 1.91 A; A=1-273.
DR   PDBsum; 1IA8; -.
DR   PDBsum; 1NVQ; -.
DR   PDBsum; 1NVR; -.
DR   PDBsum; 1NVS; -.
DR   PDBsum; 1ZLT; -.
DR   PDBsum; 1ZYS; -.
DR   PDBsum; 2AYP; -.
DR   PDBsum; 2BR1; -.
DR   PDBsum; 2BRB; -.
DR   PDBsum; 2BRG; -.
DR   PDBsum; 2BRH; -.
DR   PDBsum; 2BRM; -.
DR   PDBsum; 2BRN; -.
DR   PDBsum; 2BRO; -.
DR   PDBsum; 2C3J; -.
DR   PDBsum; 2C3K; -.
DR   PDBsum; 2C3L; -.
DR   PDBsum; 2CGU; -.
DR   PDBsum; 2CGV; -.
DR   PDBsum; 2CGW; -.
DR   PDBsum; 2CGX; -.
DR   PDBsum; 2E9N; -.
DR   PDBsum; 2E9O; -.
DR   PDBsum; 2E9P; -.
DR   PDBsum; 2E9U; -.
DR   PDBsum; 2E9V; -.
DR   PDBsum; 2GDO; -.
DR   PDBsum; 2GHG; -.
DR   PDBsum; 2HOG; -.
DR   PDBsum; 2HXL; -.
DR   PDBsum; 2HXQ; -.
DR   PDBsum; 2HY0; -.
DR   PDBsum; 2QHM; -.
DR   PDBsum; 2QHN; -.
DR   PDBsum; 2R0U; -.
DR   PDBsum; 2WMQ; -.
DR   PDBsum; 2WMR; -.
DR   PDBsum; 2WMS; -.
DR   PDBsum; 2WMT; -.
DR   PDBsum; 2WMU; -.
DR   PDBsum; 2WMV; -.
DR   PDBsum; 2WMW; -.
DR   PDBsum; 2WMX; -.
DR   PDBsum; 2X8D; -.
DR   PDBsum; 2X8E; -.
DR   PDBsum; 2X8I; -.
DR   PDBsum; 2XEY; -.
DR   PDBsum; 2XEZ; -.
DR   PDBsum; 2XF0; -.
DR   PDBsum; 2YDI; -.
DR   PDBsum; 2YDJ; -.
DR   PDBsum; 2YDK; -.
DR   PDBsum; 2YER; -.
DR   PDBsum; 2YEX; -.
DR   PDBsum; 2YM3; -.
DR   PDBsum; 2YM4; -.
DR   PDBsum; 2YM5; -.
DR   PDBsum; 2YM6; -.
DR   PDBsum; 2YM7; -.
DR   PDBsum; 2YM8; -.
DR   PDBsum; 2YWP; -.
DR   PDBsum; 3F9N; -.
DR   PDBsum; 3JVR; -.
DR   PDBsum; 3JVS; -.
DR   PDBsum; 3NLB; -.
DR   PDBsum; 3OT3; -.
DR   PDBsum; 3OT8; -.
DR   PDBsum; 3PA3; -.
DR   PDBsum; 3PA4; -.
DR   PDBsum; 3PA5; -.
DR   PDBsum; 3TKH; -.
DR   PDBsum; 3TKI; -.
DR   PDBsum; 3U9N; -.
DR   PDBsum; 4FSM; -.
DR   PDBsum; 4FSN; -.
DR   PDBsum; 4FSQ; -.
DR   PDBsum; 4FSR; -.
DR   PDBsum; 4FST; -.
DR   PDBsum; 4FSU; -.
DR   PDBsum; 4FSW; -.
DR   PDBsum; 4FSY; -.
DR   PDBsum; 4FSZ; -.
DR   PDBsum; 4FT0; -.
DR   PDBsum; 4FT3; -.
DR   PDBsum; 4FT5; -.
DR   PDBsum; 4FT7; -.
DR   PDBsum; 4FT9; -.
DR   PDBsum; 4FTA; -.
DR   PDBsum; 4FTC; -.
DR   PDBsum; 4FTI; -.
DR   PDBsum; 4FTJ; -.
DR   PDBsum; 4FTK; -.
DR   PDBsum; 4FTL; -.
DR   PDBsum; 4FTM; -.
DR   PDBsum; 4FTN; -.
DR   PDBsum; 4FTO; -.
DR   PDBsum; 4FTQ; -.
DR   PDBsum; 4FTR; -.
DR   PDBsum; 4FTT; -.
DR   PDBsum; 4FTU; -.
DR   PDBsum; 4GH2; -.
DR   PDBsum; 4HYH; -.
DR   PDBsum; 4HYI; -.
DR   PDBsum; 4JIK; -.
DR   PDBsum; 4QYE; -.
DR   PDBsum; 4QYF; -.
DR   PDBsum; 4QYG; -.
DR   PDBsum; 4QYH; -.
DR   PDBsum; 4RVK; -.
DR   PDBsum; 4RVL; -.
DR   PDBsum; 4RVM; -.
DR   PDBsum; 5DLS; -.
DR   PDBsum; 5F4N; -.
DR   ProteinModelPortal; O14757; -.
DR   SMR; O14757; -.
DR   BioGrid; 107536; 91.
DR   DIP; DIP-24182N; -.
DR   IntAct; O14757; 36.
DR   MINT; MINT-1179072; -.
DR   STRING; 9606.ENSP00000388648; -.
DR   BindingDB; O14757; -.
DR   ChEMBL; CHEMBL4630; -.
DR   DrugBank; DB07037; (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL.
DR   DrugBank; DB07228; 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA.
DR   DrugBank; DB07038; 2-(cyclohexylamino)benzoic acid.
DR   DrugBank; DB08779; 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol.
DR   DrugBank; DB07959; 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE.
DR   DrugBank; DB07075; 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE.
DR   DrugBank; DB07025; 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE.
DR   DrugBank; DB06852; 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE.
DR   DrugBank; DB07336; 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL.
DR   DrugBank; DB08780; 6-MORPHOLIN-4-YL-9H-PURINE.
DR   DrugBank; DB05149; XL844.
DR   GuidetoPHARMACOLOGY; 1987; -.
DR   iPTMnet; O14757; -.
DR   PhosphoSitePlus; O14757; -.
DR   BioMuta; CHEK1; -.
DR   EPD; O14757; -.
DR   MaxQB; O14757; -.
DR   PaxDb; O14757; -.
DR   PeptideAtlas; O14757; -.
DR   PRIDE; O14757; -.
DR   DNASU; 1111; -.
DR   Ensembl; ENST00000428830; ENSP00000412504; ENSG00000149554. [O14757-1]
DR   Ensembl; ENST00000438015; ENSP00000388648; ENSG00000149554. [O14757-1]
DR   Ensembl; ENST00000524737; ENSP00000432890; ENSG00000149554. [O14757-1]
DR   Ensembl; ENST00000532449; ENSP00000481616; ENSG00000149554. [O14757-3]
DR   Ensembl; ENST00000534070; ENSP00000435371; ENSG00000149554. [O14757-1]
DR   Ensembl; ENST00000544373; ENSP00000442317; ENSG00000149554. [O14757-2]
DR   GeneID; 1111; -.
DR   KEGG; hsa:1111; -.
DR   UCSC; uc001qcf.5; human. [O14757-1]
DR   CTD; 1111; -.
DR   DisGeNET; 1111; -.
DR   GeneCards; CHEK1; -.
DR   H-InvDB; HIX0201657; -.
DR   HGNC; HGNC:1925; CHEK1.
DR   HPA; HPA044364; -.
DR   MIM; 603078; gene.
DR   neXtProt; NX_O14757; -.
DR   OpenTargets; ENSG00000149554; -.
DR   PharmGKB; PA110; -.
DR   eggNOG; KOG0590; Eukaryota.
DR   eggNOG; ENOG410XQ0D; LUCA.
DR   GeneTree; ENSGT00870000136514; -.
DR   HOGENOM; HOG000216658; -.
DR   HOVERGEN; HBG002590; -.
DR   InParanoid; O14757; -.
DR   KO; K02216; -.
DR   OMA; GGFSKHI; -.
DR   PhylomeDB; O14757; -.
DR   TreeFam; TF351441; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   SignaLink; O14757; -.
DR   SIGNOR; O14757; -.
DR   ChiTaRS; CHEK1; human.
DR   EvolutionaryTrace; O14757; -.
DR   GeneWiki; CHEK1; -.
DR   GenomeRNAi; 1111; -.
DR   PRO; PR:O14757; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000149554; -.
DR   CleanEx; HS_CHEK1; -.
DR   ExpressionAtlas; O14757; baseline and differential.
DR   Genevisible; O14757; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:CAFA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035402; F:histone kinase activity (H3-T11 specific); IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IMP:CACAO.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0048096; P:chromatin-mediated maintenance of transcription; ISS:UniProtKB.
DR   GO; GO:0000077; P:DNA damage checkpoint; IDA:UniProtKB.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IMP:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0031572; P:G2 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0045839; P:negative regulation of mitotic nuclear division; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:CAFA.
DR   GO; GO:0010569; P:regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:2000615; P:regulation of histone H3-K9 acetylation; ISS:UniProtKB.
DR   GO; GO:0046602; P:regulation of mitotic centrosome separation; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0010767; P:regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage; ISS:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; NAS:BHF-UCL.
DR   CDD; cd14069; STKc_Chk1; 1.
DR   InterPro; IPR034670; Chk1_catalytic_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Complete proteome; Cytoplasm; Cytoskeleton; DNA damage; DNA repair;
KW   Isopeptide bond; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN         1    476       Serine/threonine-protein kinase Chk1.
FT                                /FTId=PRO_0000085848.
FT   DOMAIN        9    265       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      15     23       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    265       Interaction with CLSPN. {ECO:0000250}.
FT   REGION      391    476       Autoinhibitory region.
FT   ACT_SITE    130    130       Proton acceptor.
FT   BINDING      38     38       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     280    280       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     286    286       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     296    296       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:15707391}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     317    317       Phosphoserine; by ATM and ATR.
FT                                {ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12446774,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:12660173,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:14657349,
FT                                ECO:0000269|PubMed:15707391,
FT                                ECO:0000269|PubMed:15870257}.
FT   MOD_RES     331    331       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     345    345       Phosphoserine; by ATM and ATR.
FT                                {ECO:0000269|PubMed:10859164,
FT                                ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12446774,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676925,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:14681223,
FT                                ECO:0000269|PubMed:14988723,
FT                                ECO:0000269|PubMed:15650047,
FT                                ECO:0000269|PubMed:15707391,
FT                                ECO:0000269|PubMed:15870257,
FT                                ECO:0000269|PubMed:19716789}.
FT   MOD_RES     467    467       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     468    468       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    436    436       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:19716789}.
FT   VAR_SEQ       1     94       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:22184239}.
FT                                /FTId=VSP_044008.
FT   VAR_SEQ      95     97       RIE -> MEK (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:22184239}.
FT                                /FTId=VSP_044009.
FT   VAR_SEQ     412    445       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045075.
FT   VARIANT     156    156       R -> Q (in dbSNP:rs3731410).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_021123.
FT   VARIANT     223    223       E -> V (in dbSNP:rs35817404).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040407.
FT   VARIANT     312    312       V -> M (in dbSNP:rs34097480).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040408.
FT   VARIANT     471    471       I -> V (in dbSNP:rs506504).
FT                                {ECO:0000269|PubMed:10717241,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19054851,
FT                                ECO:0000269|PubMed:9278511,
FT                                ECO:0000269|PubMed:9382850,
FT                                ECO:0000269|Ref.6, ECO:0000269|Ref.9}.
FT                                /FTId=VAR_024571.
FT   MUTAGEN      38     38       K->R: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:12446774,
FT                                ECO:0000269|PubMed:14681223}.
FT   MUTAGEN     130    130       D->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:10673501,
FT                                ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:11535615,
FT                                ECO:0000269|PubMed:11821419,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:14681206,
FT                                ECO:0000269|PubMed:15311285,
FT                                ECO:0000269|PubMed:9278511}.
FT   MUTAGEN     317    317       S->A: Abrogates interaction with RAD51;
FT                                when associated with A-345. Reduces
FT                                phosphorylation and impairs activation by
FT                                hydroxyurea and ionizing radiation.
FT                                Abrogates nuclear retention upon
FT                                checkpoint activation. Impairs
FT                                interaction with FBXO6.
FT                                {ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:15665856}.
FT   MUTAGEN     317    317       S->E: Enhances interaction with RAD51;
FT                                when associated with E-345.
FT                                {ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:15665856}.
FT   MUTAGEN     344    344       F->A: Impairs nuclear export.
FT                                {ECO:0000269|PubMed:12676962}.
FT   MUTAGEN     345    345       S->A: Abrogates interaction with RAD51;
FT                                when associated with A-317. Reduces
FT                                phosphorylation and impairs activation by
FT                                hydroxyurea and ionizing radiation.
FT                                Impairs interaction with YWHAZ which is
FT                                required for nuclear retention after
FT                                checkpoint activation.
FT                                {ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:15665856,
FT                                ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     345    345       S->E: Enhances interaction with RAD51;
FT                                when associated with E-317.
FT                                {ECO:0000269|PubMed:11390642,
FT                                ECO:0000269|PubMed:12588868,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12676962,
FT                                ECO:0000269|PubMed:15665856,
FT                                ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     353    353       M->A: Impairs nuclear export.
FT                                {ECO:0000269|PubMed:12676962}.
FT   MUTAGEN     357    357       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT                                {ECO:0000269|PubMed:11390642}.
FT   MUTAGEN     366    366       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT                                {ECO:0000269|PubMed:11390642}.
FT   MUTAGEN     372    372       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-376 and E-379.
FT                                {ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     376    376       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-372 and E-379.
FT                                {ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     379    379       R->E: In 3RE mutant. Disrupts the folding
FT                                and/or conformation, allowing increased
FT                                accessibility to FBXO6 component of SCF-
FT                                type E3 ubiquitin ligase complex; when
FT                                associated with E-372 and E-376.
FT                                {ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     436    436       K->R: Enhances stability of the protein,
FT                                probably by preventing ubiquitination at
FT                                this site. {ECO:0000269|PubMed:19716789}.
FT   MUTAGEN     468    468       S->A: No effect on phosphorylation
FT                                induced by hydroxyurea.
FT                                {ECO:0000269|PubMed:11390642}.
FT   CONFLICT    163    163       L -> S (in Ref. 5; BAG56691).
FT                                {ECO:0000305}.
FT   CONFLICT    220    220       D -> G (in Ref. 4; BAG61665).
FT                                {ECO:0000305}.
FT   CONFLICT    381    381       F -> L (in Ref. 4; BAG61665).
FT                                {ECO:0000305}.
FT   HELIX         3      8       {ECO:0000244|PDB:2YEX}.
FT   STRAND        9     17       {ECO:0000244|PDB:2YEX}.
FT   STRAND       19     28       {ECO:0000244|PDB:2YEX}.
FT   TURN         29     31       {ECO:0000244|PDB:2YEX}.
FT   STRAND       34     41       {ECO:0000244|PDB:2YEX}.
FT   HELIX        42     44       {ECO:0000244|PDB:2YEX}.
FT   HELIX        48     60       {ECO:0000244|PDB:2YEX}.
FT   STRAND       70     76       {ECO:0000244|PDB:2YEX}.
FT   STRAND       79     85       {ECO:0000244|PDB:2YEX}.
FT   STRAND       88     91       {ECO:0000244|PDB:2GDO}.
FT   HELIX        92     95       {ECO:0000244|PDB:2YEX}.
FT   TURN         98    100       {ECO:0000244|PDB:2YEX}.
FT   HELIX       104    123       {ECO:0000244|PDB:2YEX}.
FT   STRAND      125    127       {ECO:0000244|PDB:2GHG}.
FT   HELIX       133    135       {ECO:0000244|PDB:2YEX}.
FT   STRAND      136    138       {ECO:0000244|PDB:2YEX}.
FT   STRAND      144    146       {ECO:0000244|PDB:2YEX}.
FT   HELIX       149    151       {ECO:0000244|PDB:2C3J}.
FT   STRAND      153    157       {ECO:0000244|PDB:3JVR}.
FT   HELIX       171    173       {ECO:0000244|PDB:2YEX}.
FT   HELIX       176    179       {ECO:0000244|PDB:2YEX}.
FT   STRAND      182    184       {ECO:0000244|PDB:2YEX}.
FT   HELIX       186    203       {ECO:0000244|PDB:2YEX}.
FT   STRAND      209    211       {ECO:0000244|PDB:4HYI}.
FT   STRAND      213    215       {ECO:0000244|PDB:2XEY}.
FT   HELIX       216    222       {ECO:0000244|PDB:2YEX}.
FT   STRAND      227    229       {ECO:0000244|PDB:2E9U}.
FT   HELIX       231    233       {ECO:0000244|PDB:2YEX}.
FT   HELIX       236    245       {ECO:0000244|PDB:2YEX}.
FT   TURN        250    252       {ECO:0000244|PDB:2YEX}.
FT   HELIX       256    259       {ECO:0000244|PDB:2YEX}.
FT   TURN        263    266       {ECO:0000244|PDB:2YEX}.
SQ   SEQUENCE   476 AA;  54434 MW;  0ABD0FAB67E60F67 CRC64;
     MAVPFVEDWD LVQTLGEGAY GEVQLAVNRV TEEAVAVKIV DMKRAVDCPE NIKKEICINK
     MLNHENVVKF YGHRREGNIQ YLFLEYCSGG ELFDRIEPDI GMPEPDAQRF FHQLMAGVVY
     LHGIGITHRD IKPENLLLDE RDNLKISDFG LATVFRYNNR ERLLNKMCGT LPYVAPELLK
     RREFHAEPVD VWSCGIVLTA MLAGELPWDQ PSDSCQEYSD WKEKKTYLNP WKKIDSAPLA
     LLHKILVENP SARITIPDIK KDRWYNKPLK KGAKRPRVTS GGVSESPSGF SKHIQSNLDF
     SPVNSASSEE NVKYSSSQPE PRTGLSLWDT SPSYIDKLVQ GISFSQPTCP DHMLLNSQLL
     GTPGSSQNPW QRLVKRMTRF FTKLDADKSY QCLKETCEKL GYQWKKSCMN QVTISTTDRR
     NNKLIFKVNL LEMDDKILVD FRLSKGDGLE FKRHFLKIKG KLIDIVSSQK IWLPAT
//
